CLAIMS

1. Promoter comprising the nucleic acid sequence SEQ ID NO:1, in which a fragment starting from position A and ending at position B of said sequence SEQ ID NO:1 has been substituted by a fragment of the hEF1α promoter comprising at least the TATA box,
wherein position A is comprised between nucleotides 521 and 555 of SEQ ID NO:1, and position B is comprised between nucleotides 560 and 587 of SEQ ID NO:1, and
wherein the fragment consisting of nucleotides 598 to 607 of SEQ ID NO:1 may be present or absent.

2. Promoter according to claim 1, wherein the fragment of the hEF1α promoter comprising at least the TATA box is chosen from sequences SEQ ID NO:2, 3 and 4.

3. Promoter according to any one of claims 1 to 2, wherein the fragment starting from nucleotide 541 and ending at nucleotide 560 of sequence SEQ ID NO:1 has been substituted by the fragment of the hEF1α promoter comprising at least the TATA box of sequence SEQ ID NO:2, and
the fragment consisting of nucleotides 598 to 607 of SEQ ID NO:1 is absent.

4. Promoter according to any one of claims 1 to 2, wherein the fragment starting from nucleotide 541 and ending at nucleotide 560 of sequence SEQ ID NO:1 has been substituted by the fragment of the hEF1α promoter comprising at least the TATA box of sequence SEQ ID NO:2, and
the fragment consisting of nucleotides 598 to 607 of SEQ ID NO:1 is present.

5. Promoter according to any one of claims 1 to 2, wherein the fragment starting from nucleotide 555 and ending at nucleotide 560 of sequence SEQ ID NO:1 has been substituted by the fragment of the hEF1α promoter comprising at least the TATA box of sequence SEQ ID NO:3, and
the fragment consisting of nucleotides 598 to 607 of SEQ ID NO:1 is absent.

6. Promoter according to any one of claims 1 to 2, wherein the fragment starting from nucleotide 555 and ending at nucleotide 560 of sequence SEQ ID NO:1 has been substituted by the fragment of the hEF1α promoter comprising at least the TATA box of sequence SEQ ID NO:3, and
the fragment consisting of nucleotides 598 to 607 of SEQ ID NO:1 is present.

7. Promoter according to any one of claims 1 to 2, wherein the fragment starting from nucleotide 521 and ending at nucleotide 587 of sequence SEQ ID NO:1 has been substituted by the fragment of the hEF1α promoter comprising at least the TATA box of sequence SEQ ID NO:4, and
the fragment consisting of nucleotides 598 to 607 of SEQ ID NO:1 is absent.

8. Promoter according to any one of claims 1 to 2, wherein the fragment starting from nucleotide 521 and ending at nucleotide 587 of sequence SEQ ID NO:1 has been substituted by the fragment of the hEF1α promoter comprising at least the TATA box of sequence SEQ ID NO:4, and
the fragment consisting of nucleotides 598 to 607 of SEQ ID NO:1 is present.

9. Promoter comprising the nucleic acid sequence SEQ ID NO:17 or SEQ ID NO:29, or comprising the nucleic acid sequence SEQ ID NO:5, in which the sequence SEQ ID NO: 7 has been inserted between nucleotides 89 and 90 of said sequence SEQ ID NO:5, and the fragment starting from nucleotide 104 and ending at nucleotide 153 of said sequence SEQ ID NO:5 has been substituted by the sequence SEQ ID NO:7, and optionally the sequence SEQ ID NO:8 has been inserted between nucleotides 217 and 218 of SEQ ID NO:5.

10. Vector comprising the promoter according to any one of claims 1 to 9.

11. Vector according to claim 10, in which the promoter controls the expression of a gene or a fragment thereof coding for a collagen chain, preferably COL2A1.

12. Promoter according to any one of claims 1 to 9, or vector according to claim 10 or 11, for use in therapy.

13. Promoter according to any one of claims 1 to 9, or vector according to claim 10 or 11, for use in gene therapy.

14. Use of the promoter according to any one of claims 1 to 9, or the vector according to claim 10 or 11, in the manufacture of a medicament for treating a skeletal dysplasia or a disease of the musculoskeletal system.

15. Use of the promoter according to any one of claims 1 to 9 or 14, or the vector according to claim 10 or 11 or 14, in the manufacture of a medicament for treating a type II collagenopathy.